Posted by Michael Wonder on 16 Sep 2023
Merck receives positive EU CHMP opinion for Keytruda (pembrolizumab) as adjuvant treatment for adults with non-small cell lung cancer at high risk of recurrence following complete resection and platinum-based chemotherapy
15 September 2023 - Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial.
Merck today announced that the EMA’s CHMP adopted a positive opinion recommending approval of Keytruda, Merck’s anti-PD-1 therapy, for the adjuvant treatment of adults with non-small cell lung cancer, who are at high risk of recurrence following complete resection and platinum-based chemotherapy.
